It is hoped that by coupling trastuzumab (Herceptin; Genentech/Roche) — a humanized monoclonal antibody (mAb) specific for the human epidermal growth factor receptor 2 (HER2; also known as ERBB2 ...

The study drug was compared to the chemotherapy Taxol combined with Perjeta and another Roche monoclonal antibody drug, Herceptin. This three-drug combination is a standard first-line treatment ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab ... from successfully launching two previous monoclonal antibody biosimilars.” ...

Rwanda is set to become home to Africa’s first manufacturing plant for eye care products and monoclonal ... at the plant is Herceptin (Trastuzumab), a monoclonal antibody used in breast cancer ...

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab ... "The biggest category of medicines in oncology is monoclonal antibodies and the introduction of biosimilars such ...

In radioimmunotherapy, a radioisotope is coupled to a monoclonal antibody to form a tumor-specific targeting agent. [45] The principle can be useful in diagnostics by visualizing tumor uptake and ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.